Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC).
The aim of the single-arm, open-label, phase II clinical trial is to evaluate the efficacy
and safety of lenvatinib as an adjuvant therapy for patients underwent radical resection of
HCC with a high risk of tumor recurrence.
Investigator hypothesize that lenvatinib may be an effective adjuvant treatment for HCC, and
12-month adjuvant treatment with lenvatinib can improve one-year recurrence-free survival
rate (RFS) of HCC patients after surgical resection.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborators:
Anhui Provincial Hospital Tongji Hospital West China Hospital